This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Anthony Shock
Director at UCB Pharma


Anthony Shock received his PhD in Biochemistry from the University of London in 1987 followed by post-doctoral work at the National Heart & Lung Institute in London. He was then employed by a Biotech company called Celltech which eventually transformed into the global biopharmaceutical company, UCB. He has researched on a wide range of antibody-based therapies, including two antibody targets that have been evaluated in patients with systemic lupus erythematosus, epratuzumab and dapirolizumab pegol, and rozanolixizumab which is currently undergoing phase 3 clinical evaluation in patients with immune thrombocytopenia & myasthenia gravis, which are autoimmune disorders driven by IgG autoantibodies.

Agenda Sessions

  • Rozanolixizumab, A Subcutaneously Delivered IgG4 mAb Targeting FcRn for the Treatment of IgG Autoantibody-driven disorders